Annovis Bio, Inc. (ANVS) Stock Price & Analysis
Annovis Bio, Inc. (ANVS) fell 1.12% to USD 1.77 as of June 10, 2026 at 06:02 UTC, according to Nexqual real-time market data.
ANVS last closed at USD 1.79; the session ranged USD 1.71–1.84 on volume of 1,187,562 shares. Market capitalization is $75.30M, with a 52-week range of USD 1.54–5.5 (NYQ). Source: Nexqual, June 10, 2026 at 06:02 UTC.
Key Statistics (as of June 10, 2026 at 06:02 UTC)
| Price | USD 1.77 |
|---|---|
| Change | ▼ 1.12% (down) |
| Previous Close | USD 1.79 |
| Open | USD 1.78 |
| Day Range | USD 1.71 – 1.84 |
| 52-Week Range | USD 1.54 – 5.5 |
| Volume | 1,187,562 shares |
| Market Cap | $75.30M |
| Exchange | NYQ |
Technical Analysis (ANVS)
Nexqual's technical model rates ANVS "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 06:02 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.67 (neutral) |
| vs SMA50 | Below (USD 2.01) |
| MACD | -0.07 (negative) |
Analyst Ratings (ANVS)
Wall Street analysts rate ANVS "Strong Buy" based on 2 analysts, with a mean price target of USD 12.5 (range USD 8–17), per Nexqual as of June 10, 2026 at 06:02 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 12.5 |
| High Target | USD 17 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (ANVS)
| EPS Estimate | USD -0.48 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.63 vs est -0.35 ▼ miss |
| 2025-12-31 | USD -0.39 vs est -0.3 ▼ miss |
| 2025-09-30 | USD -0.37 vs est -0.37 ▲ beat |
| 2025-06-30 | USD -0.32 vs est -0.39 ▲ beat |
Source: Nexqual, June 10, 2026 at 06:02 UTC.
Financials & Fundamentals (ANVS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -220.61% |
| Current Ratio | 5.8 |
| Total Cash | $19.53M |
| Total Debt | $0 |
| Free Cash Flow | $-15.18M |
Source: Nexqual, June 10, 2026 at 06:02 UTC.
Financial Health Score (ANVS)
Nexqual rates Annovis Bio, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 06:02 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $20M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$26M |
| Efficiency | Critical — ROE -221%, ROA -106.0% |
Ownership (ANVS)
| Insider Ownership | +14.10% |
|---|---|
| Institutional Ownership | +16.71% |
| Shares Outstanding | 42.54M |
| Float | 25.10M |
| Short % of Float | +12.95% |
Source: Nexqual, June 10, 2026 at 06:02 UTC.
Leadership (ANVS)
Annovis Bio, Inc. is led by Maria L. Maccecchini (age 74), Founder, Acting CFO, CEO, President & Executive Director, per Nexqual as of June 10, 2026 at 06:02 UTC.
| Founder, Acting CFO, CEO, President & Executive Director | Maria L. Maccecchini (age 74) |
|---|---|
| Senior Vice President of Research & Development | Cheng Fang |
| Senior Vice President of Regulatory Operations | Eve M. Damiano M.S., RAC |
| Senior Vice President of Statistics | Hilda Maibach |
Major Backers & Investors (ANVS)
Notable institutional backers of Annovis Bio, Inc. include Marshall Wace LLP, Two Sigma Investments, LP, Renaissance Technologies, according to Nexqual as of June 10, 2026 at 06:02 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Marshall Wace LLP | 3.43% |
| Two Sigma Investments, LP | 1.81% |
| Renaissance Technologies | 1% |
| Susquehanna International Group, LLP | 0.63% |
| Fidelity | 0.57% |
| Merit Financial Group, LLC | 0.23% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.42% |
| Geode Capital | 0.71% |
| Northern Trust | 0.41% |
| BlackRock | 0.4% |
Source: Nexqual, June 10, 2026 at 06:02 UTC.
From Annovis Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-13)
Key Strengths & Strategy (as disclosed to the SEC)
- We believe that we are the only company developing a drug for AD and PD that inhibits more than one neurotoxic protein and has a mechanism of action designed to restore nerve cell axonal and synaptic activity.
Partnerships
- In collaboration with the Alzheimer's Disease Cooperative Study ("ADCS"), we also conducted a trial in 16 early AD 5 Table of Contents patients (the "ADCS Trial").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AVXL | Anavex Life Sciences Corp. | USD 2.54 | ▼ 1.17% |
| INMB | INmune Bio Inc. | USD 1.22 | ▼ 3.17% |
| FLNA | Filana Therapeutics, Inc. | USD 1.42 | ▲ 7.58% |
| ACIU | AC Immune SA | USD 2.26 | ▲ 0.44% |
| LGVN | Longeveron Inc. | USD 0.77 | ▲ 5.89% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:02 UTC. This page is informational and not investment advice.